Cite
HARVARD Citation
Chakrabarti, S. et al. (2022). Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management. Expert opinion on drug metabolism and toxicology. pp. 85-98. [Online].